Basic and clinical studies of biapenem

Abstract

We studied the antibacterial activity and clinical efficacy of biapenem (BIPM), a new carbapenem antibiotic.
1) Antibacterial activity:
The MIC of BIPM against 319 clinical isolates of 9 species were compared with those of imipenem (IPM), piperacillin (PIPC), ceftazidime (CAZ).
59 strains of methicillin-resistant Staphylococcus arureus (MRSA) against BIPM showed susceptible distribution of 0.0625-128μg/ml (with the peak of 4μg/ml), 67 strains of methicillin-sensitive Staphylococcus arureus (MSSA) 0.0625-0.5μg/ml (0.125μg/ml), and 22 strains of Enterococcus faecalis 0.0625-32μg/ml (1μg/ml), exhibiting one or two fold less activity of BIPM than that of IPM.
24 strains of Staphylococcus epidermidis showed a distribution of 0.0625-64μg/ml with the peak of 0.0625μg/ml.
63 strains of Pseudomonas aeruginosa showed a distribution of 0.0625-16μg/ml (with the peak of 1μg/ml), 16 strains of Serratia marcescens 0.0625-4μg/ml (1μg/ml), 24 strains of Klebsiella pneumoniae 0.0625-0.5μg/ml (0.0625μg/ml), 33 strains of E. coli 0.0625 yernl (0.0625μg/ml), and 11 strains of Acinetobacter calcoaceticus 0.0625-0.25μg/ml (0.125μg/ml), exhibiting that the antibacterial activity of BIPM was superior to IPM.
2) Clinical study:
BIPM was administered to 7 patients (bacterial pneumonia in 5, pneumoniosis +infection in 1, and chronic bronchitis in 1) at a dose of 0.6g per day for 14 days.
The clinical efficacy was excellept in 6 cases and unknown in 1 case.
Adverse reaction was observed with rash in 1 case.
Abnormal laboratory finding were observed with eosinophilia in 2 cases.